Why Amylyx Pharmaceuticals, Inc.’s (AMLX) Stock Is Down 5.58%
As of Wednesday, September 23, Amylyx Pharmaceuticals, Inc.’s AMLX share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Jenna Brashear
Stock Evaluator: Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. AMLX
$27.43
-0.61
-2.18%
October 7, 2026 4:00:00 PM
EST
Volume: 2,056,628
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Commentary & Analysis
Why Amylyx Pharmaceuticals, Inc.’s (AMLX) Stock Is Up 10.03%
As of Wednesday, August 19, Amylyx Pharmaceuticals, Inc.’s AMLX share price has surged by 10.03%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Amylyx Pharmaceuticals, Inc.’s (AMLX) Stock Is Up 33.19%
As of Tuesday, August 18, Amylyx Pharmaceuticals, Inc.’s AMLX share price has surged by 33.19%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Amylyx Pharmaceuticals, Inc.’s (AMLX) Stock Is Up 48.86%
As of Tuesday, August 18, Amylyx Pharmaceuticals, Inc.’s AMLX share price has surged by 48.86%, which has investors questioning if this is right time to sell.Tudor Pop
Why Amylyx Pharmaceuticals, Inc.’s (AMLX) Stock Is Up 8.19%
As of Thursday, August 06, Amylyx Pharmaceuticals, Inc.’s AMLX share price has surged by 8.19%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,519.4 | $538.3 | 62% |
|
| Shares Out (Mil) | 111.2 | 42.8 | 64% |
|
| Institutional Ownership | 93.3% | 82.8% | 63% |
|
| Float (Mil) | 109.5 | 44.5 | 63% |
|
| Beta | -0.12 | 0.70 | 4% |
|
| Avg Daily Volume (000s) | 1,253 | 371 | 73% |
|
| Price Change (52-week) |
108.9% | 58.2% | 95% |
|
| Growth | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (27.9%) | (2.0%) | 15% |
|
| EPS (5yr) | 26.1% | 15.0% | 77 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (0.9%) | (15.1%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.375) | ($1.497) | ($1.155) | |
| Month Ago EPS | ($0.375) | ($1.497) | ($1.155) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.335) | ($1.385) | ($1.266) | |
| Year/Year Chg | (4.1%) | (2.2%) | (55.5%) | |
| Financials | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($152) | ($11) | 8% |
|
| EPS (TTM) | ($1.431) | ($0.700) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($127) | ($7) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $6 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $6 | 24% |
|
| Enterprise Value (Q1) (Mil) | $3,822 | $494 | 58% |
|
| Valuation | AMLX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 13.04 | 2.29 | 93% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (66.2%) | (22.2%) | 9% |
|
| ROE | (74.7%) | (21.0%) | 12% |
|
| Liabilities to Assets | 9.6% | 33.9% | 6% |
|
| F-Score | 3 | 3 | 18% |
|
Amylyx Pharmaceuticals, Inc. did not pass any screens on 10/6/2026.
